M H Weisman

Summary

Affiliation: Cedars-Sinai Medical Center
Country: USA

Publications

  1. pmc Newly diagnosed rheumatoid arthritis
    M H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Rheum Dis 61:287-9. 2002
  2. ncbi request reprint Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Rheum 54:607-12. 2006
  3. pmc Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort
    Wonuk Lee
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Rheum Dis 66:633-8. 2007
  4. pmc New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus
    Fang Fang Wang
    Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 145 Middle Shan Dong Road, Shanghai 200001, China
    Arthritis Res Ther 14:R103. 2012
  5. pmc Heritability patterns in hand osteoarthritis: the role of osteophytes
    Mariko L Ishimori
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    Arthritis Res Ther 12:R180. 2010
  6. pmc The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study
    Matthew L Mundwiler
    North Suburban Rheumatologists, Des Plaines, IL 60016, USA
    Arthritis Res Ther 11:R94. 2009
  7. pmc Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
    Matthew L Mundwiler
    Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA
    Arthritis Res Ther 11:R177. 2009
  8. doi request reprint Development and validation of a case ascertainment tool for ankylosing spondylitis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Care Res (Hoboken) 62:19-27. 2010
  9. ncbi request reprint Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    J Rheumatol 33:2162-6. 2006
  10. ncbi request reprint Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Ther 25:1700-21. 2003

Detail Information

Publications56

  1. pmc Newly diagnosed rheumatoid arthritis
    M H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Rheum Dis 61:287-9. 2002
  2. ncbi request reprint Risk genotypes in folate-dependent enzymes and their association with methotrexate-related side effects in rheumatoid arthritis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Rheum 54:607-12. 2006
    ..This study investigated whether risk genotypes for folate-dependent enzymes are associated with the toxicity of MTX in patients with rheumatoid arthritis (RA)...
  3. pmc Are there gender differences in severity of ankylosing spondylitis? Results from the PSOAS cohort
    Wonuk Lee
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Ann Rheum Dis 66:633-8. 2007
    ....
  4. pmc New insights into the role and mechanism of macrophage migration inhibitory factor in steroid-resistant patients with systemic lupus erythematosus
    Fang Fang Wang
    Department of Rheumatology, Renji Hospital, Shanghai Jiaotong University School of Medicine, 145 Middle Shan Dong Road, Shanghai 200001, China
    Arthritis Res Ther 14:R103. 2012
    ..In the present study, we investigated for the first time whether MIF correlated with steroid resistance in SLE and explored potential mechanisms of action...
  5. pmc Heritability patterns in hand osteoarthritis: the role of osteophytes
    Mariko L Ishimori
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    Arthritis Res Ther 12:R180. 2010
    ..The objective of the present study was to assess heritability of clinical and radiographic features of hand osteoarthritis (OA) in affected patients and their siblings...
  6. pmc The utility of MRI in predicting radiographic erosions in the metatarsophalangeal joints of the rheumatoid foot: a prospective longitudinal cohort study
    Matthew L Mundwiler
    North Suburban Rheumatologists, Des Plaines, IL 60016, USA
    Arthritis Res Ther 11:R94. 2009
    ..Similar analyses were performed for bone marrow edema, predicting a subsequent MRI erosion. Descriptive results of other lesions are reported...
  7. pmc Inflammatory bowel disease serologies in ankylosing spondylitis patients: a pilot study
    Matthew L Mundwiler
    Rockford Orthopedic Associates, 324 Roxbury Rd, Rockford, IL 61107, USA
    Arthritis Res Ther 11:R177. 2009
    ..Because of the overlap between the two conditions, a pilot study was designed to compare the frequency of these antibodies in AS patients compared to normal controls...
  8. doi request reprint Development and validation of a case ascertainment tool for ankylosing spondylitis
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Arthritis Care Res (Hoboken) 62:19-27. 2010
    ..We tested questions derived from a comprehensive literature review and an advisory board in a case-control study designed to identify patients with AS from among patients with chronic back pain (CBP)...
  9. ncbi request reprint Reduction of inflammatory biomarker response by abatacept in treatment of rheumatoid arthritis
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, 8700 Beverly Blvd, B 131, Los Angeles, CA 90048, USA
    J Rheumatol 33:2162-6. 2006
    ..To determine the mechanism of action of abatacept, we analyzed changes in the serum levels of inflammatory biomarkers in the patients enrolled in this trial...
  10. ncbi request reprint Efficacy, pharmacokinetic, and safety assessment of adalimumab, a fully human anti-tumor necrosis factor-alpha monoclonal antibody, in adults with rheumatoid arthritis receiving concomitant methotrexate: a pilot study
    Michael H Weisman
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Clin Ther 25:1700-21. 2003
    ....
  11. ncbi request reprint Development of a new instrument for rheumatoid arthritis: the Cedars-Sinai Health-Related Quality of Life instrument (CSHQ-RA)
    Michael H Weisman
    Cedars Sinai Health System, Los Angeles, California 90048, USA
    Arthritis Rheum 49:78-84. 2003
    ....
  12. ncbi request reprint What are the risks of biologic therapy in rheumatoid arthritis? An update on safety
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Rheumatol Suppl 65:33-8. 2002
    ..At this time, treating physicians must carefully weigh the benefits of these new biologics against their risks, particularly in patients at risk of infection...
  13. pmc Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2007
    D E Furst
    David Geffen School of Medicine, UCLA RM 32 59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
    Ann Rheum Dis 66:iii2-22. 2007
  14. doi request reprint The Patient Reported Outcomes in Lupus (PATROL) study: role of depression in health-related quality of life in a Southern California lupus cohort
    I Moldovan
    Loma Linda University, California, USA
    Lupus 20:1285-92. 2011
    ..0001). Conclusion: Depression, and not disease activity, appears to have a major influence on quality of life in both Hispanic and Caucasian patients in this lupus cohort...
  15. ncbi request reprint Development and validation of the revised Cedars-Sinai health-related quality of life for rheumatoid arthritis instrument
    C F Chiou
    Cerner LifeSciences, Beverly Hills, California, USA
    Arthritis Rheum 55:856-63. 2006
    ..To improve accuracy and content coverage of the original 33-item Cedars-Sinai Health-Related Quality of Life for Rheumatoid Arthritis Instrument (CSHQ-RA)...
  16. doi request reprint Does mycophenolate mofetil prevent extra-renal flares in systemic lupus erythematosus? Results from an observational study of patients in a single practice treated for up to 5 years
    J D Posalski
    Cedars Sinai Medical Center, Los Angeles, CA, USA
    Lupus 18:516-21. 2009
    ..When evaluating organ system subsets separately, MMF improved disease activity in the first year, but had little effect in preventing new organ-specific flares, with most flares taking place in second and third year of treatment...
  17. pmc Updated consensus statement on biological agents for the treatment of rheumatic diseases, 2006
    D E Furst
    David Geffen School of Medicine, UCLA RM 32 59, 1000 Veteran Avenue, Los Angeles, CA 90025, USA
    Ann Rheum Dis 65:iii2-15. 2006
  18. ncbi request reprint Benefits of leflunomide in systemic lupus erythematosus: a pilot observational study
    C F Remer
    Division of Rheumatology, Cedars-Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 10:480-3. 2001
    ..Blood pressure was unchanged. Leflunomide was efficacious and safe in this cohort of SLE patients after 2-3 months of therapy. Placebo-controlled trials of longer duration are indicated...
  19. ncbi request reprint The B cell in systemic lupus erythaematosus: a rational target for more effective therapy
    C B Driver
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Ann Rheum Dis 67:1374-81. 2008
    ..Although many current drugs appear to modify B cell function, the advent of new, targeted therapies offers the hope of improved efficacy and a better long-term tolerability profile...
  20. doi request reprint Review: Male systemic lupus erythematosus: a review of sex disparities in this disease
    L J Lu
    Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 19:119-29. 2010
    ..This review discusses these findings and sex disparities in SLE that appear to be especially noteworthy and pertinent to our understanding of male SLE...
  21. doi request reprint High-sensitivity C-reactive protein and erythrocyte sedimentation rate in systemic lupus erythematosus
    N Firooz
    Cedars Sinai Medical Center, Los Angeles, California, USA
    Lupus 20:588-97. 2011
    ..Elevated hsCRP levels can be used as a predictor of active infection in SLE patients with a high specificity. We review the relationship between IL-6 and hsCRP production in lupus patients...
  22. ncbi request reprint Validation of a rheumatoid arthritis health-related quality of life instrument, the CSHQ-RA
    S M Russak
    Division of Rheumatology, Cedars Sinai Health System, 8700 Beverly Boulevard, Los Angeles, CA 90048, USA
    Arthritis Rheum 49:798-803. 2003
    ..To test the validity and reliability of a newly developed disease-specific multidimensional quality of life instrument: the Cedars-Sinai Health-Related Quality of Life Instrument (CSHQ-RA)...
  23. ncbi request reprint Cigarette smoking and rheumatoid arthritis
    S A Albano
    Division of Rheumatology, Department of Medicine, Cedars-Sinai Medical Center, Los Angeles, CA 90048, USA
    Semin Arthritis Rheum 31:146-59. 2001
    ..The example of p53 may be a first step in the discovery of additional links between environmental triggers and phenotypic expression of chronic illness...
  24. pmc Potential therapeutic uses of interleukin 1 receptor antagonists in human diseases
    D S Hallegua
    Cedars Sinai Medical Center UCLA School of Medicine, Los Angeles, CA 90048, USA
    Ann Rheum Dis 61:960-7. 2002
    ..To review publications relating to the blocking of interleukin 1 (IL1) as a strategy for treating human disease, ranging from rheumatoid arthritis (RA) to Alzheimer's disease...
  25. ncbi request reprint Cytokines play an aetiopathogenetic role in fibromyalgia: a hypothesis and pilot study
    D J Wallace
    Department of Medicine/Division of Rheumatology, Cedars-Sinai Medical Center/UCLA School of Medicine, Los Angeles, CA, USA
    Rheumatology (Oxford) 40:743-9. 2001
    ..Because IL-8 promotes sympathetic pain and IL-6 induces hyperalgesia, fatigue and depression, it is hypothesized that they may play a role in modulating FM symptoms...
  26. doi request reprint Depression predicts self-reported disease activity in systemic lupus erythematosus
    F N Carr
    California School of Professional Psychology, Alliant International University, Los Angeles, California, USA
    Lupus 20:80-4. 2011
    ..Longitudinally, depression alone predicted self-reported disease activity. These data suggest that depression may play a significant role in the health status of SLE patients and serve as an important target for clinical intervention...
  27. ncbi request reprint Posterior reversible encephalopathy syndrome: another manifestation of CNS SLE?
    M L Ishimori
    Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 16:436-43. 2007
    ..The therapeutic implications for separating PRES from stroke or cerebritis are important. We propose that PRES should be considered in the differential diagnosis in SLE patients with new-onset neurologic signs and symptoms...
  28. ncbi request reprint The lowest surviving birth weight reported in a systemic lupus erythematosus patient: a review of the literature
    J Spiegel
    Division of Rheumatology, Cedars Sinai Medical Center, David Geffen School of Medicine at UCLA, Los Angeles, CA, USA
    Lupus 16:52-5. 2007
    ..This report represents the lowest birth weight pregnancy survival in a lupus patient and the first case of a survival in the second trimester with preeclampsia and HELLP syndrome...
  29. ncbi request reprint Celecoxib for systemic lupus erythematosus: case series and literature review of the use of NSAIDs in SLE
    S A Lander
    Department of Medicine, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    Lupus 11:340-7. 2002
    ..These results suggest that patients with SLE can be safely and effectively treated with celecoxib; however, further studies are needed to assess the effectiveness and safety of all NSAIDs in SLE...
  30. ncbi request reprint Do all drugs and treatments for rheumatoid arthritis have the same efficacy?
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Nat Clin Pract Rheumatol 4:298-9. 2008
  31. ncbi request reprint New therapies for treatment of rheumatoid arthritis
    Josef S Smolen
    Division of Rheumatology, Department of Internal Medicine III, Medical University of Vienna, Vienna, Austria
    Lancet 370:1861-74. 2007
    ..Novel therapeutic strategies in conjunction with optimised disease assessment for better treatment of rheumatoid arthritis and an outlook into potential future targets are also presented...
  32. ncbi request reprint A placebo-controlled, randomized, double-blinded study evaluating the safety of etanercept in patients with rheumatoid arthritis and concomitant comorbid diseases
    Michael H Weisman
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Rheumatology (Oxford) 46:1122-5. 2007
    ..To evaluate the safety of etanercept in patients with rheumatoid arthritis (RA) and concomitant comorbidities...
  33. ncbi request reprint Adalimumab, a fully human anti-tumor necrosis factor alpha monoclonal antibody, for the treatment of rheumatoid arthritis in patients taking concomitant methotrexate: the ARMADA trial
    Michael E Weinblatt
    Rheumatology and Immunology, Brigham and Women s Hospital, Boston, Massachusetts 02115, USA
    Arthritis Rheum 48:35-45. 2003
    ..To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active rheumatoid arthritis (RA) despite treatment with MTX...
  34. ncbi request reprint Etanercept treatment for autoimmune inner ear disease: results of a pilot placebo-controlled study
    Stanley Cohen
    Division of Rheumatology, St Paul University Medical Center, Dallas, Texas 75235, USA
    Otol Neurotol 26:903-7. 2005
    ..Data from a guinea pig model of AIED and a recent open label trial of etanercept suggested potential treatment benefit. Based on these preliminary results, we conducted a pilot placebo controlled trial of etanercept in AIED patients...
  35. ncbi request reprint Progress toward the cure of rheumatoid arthritis? The BeSt study
    Michael H Weisman
    Arthritis Rheum 52:3326-32. 2005
  36. ncbi request reprint The PREMIER study: A multicenter, randomized, double-blind clinical trial of combination therapy with adalimumab plus methotrexate versus methotrexate alone or adalimumab alone in patients with early, aggressive rheumatoid arthritis who had not had previo
    Ferdinand C Breedveld
    Department of Rheumatology, Leiden University Medical Centre, Albinusdreef 2, C4 R Postbox 9600, Leiden 2300 RC, The Netherlands
    Arthritis Rheum 54:26-37. 2006
    ..To compare the efficacy and safety of adalimumab plus methotrexate (MTX) versus MTX monotherapy or adalimumab monotherapy in patients with early, aggressive rheumatoid arthritis (RA) who had not previously received MTX treatment...
  37. ncbi request reprint Patient retention and hand-wrist radiograph progression of rheumatoid arthritis during a 3-year prospective study that prohibited disease modifying antirheumatic drugs
    Harold E Paulus
    Division of Rheumatology, UCLA Medical Center, Los Angeles, California 90095, USA
    J Rheumatol 31:470-81. 2004
    ..To quantitate patient retention and radiographic progression rates in serial hand/wrist radiographs of patients with rheumatoid arthritis (RA) who were not being treated with disease modifying antirheumatic drugs (DMARD)...
  38. ncbi request reprint Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT)
    Christian E Antoni
    Friedrich Alexander University, Erlangen Nuremberg, Germany
    Arthritis Rheum 52:1227-36. 2005
    ..To investigate the efficacy and tolerability of infliximab therapy for the articular and dermatologic manifestations of active psoriatic arthritis (PsA)...
  39. ncbi request reprint Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial
    Joel M Kremer
    The Center for Rheumatology, LLP, 1367 Washington Avenue, Suite 101, Albany, NY 12206, USA
    Ann Intern Med 137:726-33. 2002
    ..Disease-modifying antirheumatic drugs may confer greater benefits when combined with the antimetabolite methotrexate...
  40. ncbi request reprint Treatment of corticosteroid-responsive autoimmune inner ear disease with methotrexate: a randomized controlled trial
    Jeffrey P Harris
    Division of Otolaryngology Head and Neck Surgery, University of California, San Diego, CA 92103 8895, USA
    JAMA 290:1875-83. 2003
    ..Methotrexate has emerged as the benchmark agent but has not been rigorously evaluated for hearing improvement in patients with AIED...
  41. ncbi request reprint Biomarkers, surrogate markers, and design of clinical trials of new therapies for systemic lupus erythematosus
    Joel Schiffenbauer
    Center for Drug Evaluation and Research, FDA, Rockville, Maryland 20850, USA
    Arthritis Rheum 50:2415-22. 2004
  42. ncbi request reprint Glucosamine, chondroitin sulfate, and the two in combination for painful knee osteoarthritis
    Daniel O Clegg
    Division of Rheumatology, University of Utah School of Medicine, Salt Lake City, UT 84132, USA
    N Engl J Med 354:795-808. 2006
    ..The multicenter, double-blind, placebo- and celecoxib-controlled Glucosamine/chondroitin Arthritis Intervention Trial (GAIT) evaluated their efficacy and safety as a treatment for knee pain from osteoarthritis...
  43. ncbi request reprint Hydroxychloroquine cardiotoxicity in systemic lupus erythematosus: a report of 2 cases and review of the literature
    Jessica E Nord
    Department of Psychiatry and Biobehavioral Sciences, UCLA Neuropsychiatric Institute, Los Angeles, California, USA
    Semin Arthritis Rheum 33:336-51. 2004
    ..We present 2 cases of potential cardiotoxicity occurring in patients with SLE while receiving long-term HCQ therapy...
  44. ncbi request reprint Reading and interpreting economic evaluations in rheumatoid arthritis: an assessment of selected instruments for critical appraisal
    Michael H Weisman
    Evidence Based Medicine Working Groups in Rheumatology, Beverly Hills, CA, USA
    J Rheumatol 30:1739-47. 2003
    ..To describe and compare the relative attributes (reliability, ease of use, applicability, and relevance) of different assessment tools for economic analyses as they pertain to rheumatoid arthritis (RA) literature...
  45. ncbi request reprint Lack of linkage of IL1RN genotypes with ankylosing spondylitis susceptibility
    Li Jin
    University of Cincinnati Cincinnati, OH, USA
    Arthritis Rheum 50:3047-8. 2004
  46. ncbi request reprint ASsessment in Ankylosing Spondylitis International Working Group/Spondylitis Association of America recommendations for conducting clinical trials in ankylosing spondylitis
    Desiree van der Heijde
    University Hospital Maastricht, and the Care and Public Health Research Institute of the University Maastricht, Maastricht, The Netherlands
    Arthritis Rheum 52:386-94. 2005
  47. ncbi request reprint Validity of self-administered quality of well-being scale in musculoskeletal disease
    Dominick L Frosch
    University of California, San Diego, CA, USA
    Arthritis Rheum 51:28-33. 2004
    ..To evaluate the self-administered Quality of Well-Being (QWB-SA) Scale for patients with rheumatic diseases...
  48. doi request reprint Impact of ankylosing spondylitis on work and family life: comparisons with the US population
    Michael M Ward
    National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland 20892, USA
    Arthritis Rheum 59:497-503. 2008
    ..To examine the impact of ankylosing spondylitis (AS) on work disability, nonparticipation in the labor force, marriage, divorce, and childbearing...
  49. ncbi request reprint The predictive power of anti-cyclic citrullinated peptide antibodies: window into understanding gene/ environment/immunity interactions
    Wonuk Lee
    J Rheumatol 33:1216-8. 2006
  50. ncbi request reprint Geode of the femur: an uncommon manifestation potentially reflecting the pathogenesis of rheumatoid arthritis
    Wonuk Lee
    Division of Rheumatology, Department of Radiology, Cedars Sinai Medical Center, Los Angeles, California 90048, USA
    J Rheumatol 33:2541-4. 2006
    ..We review the literature of large femoral geodes and what this particular manifestation may reflect about the pathogenesis of RA...
  51. ncbi request reprint Ruminating on rheumatoid arthritis and transplantation
    Richard K Burt
    Northwestern University, Feinberg School of Medicine, Chicago, IL 60208, USA
    Clin Immunol 115:129-30. 2005
  52. ncbi request reprint Medical signs and symptoms associated with disability, pain, and psychosocial adjustment in systemic sclerosis
    Vanessa L Malcarne
    Department of Psychology, San Diego State University, CA 92120 4913, USA
    J Rheumatol 34:359-67. 2007
    ..To examine physician-assessed medical signs and patient-reported medical symptoms as correlates of 3 quality of life (QOL) outcomes in patients with systemic sclerosis (SSc): disability, pain, and psychosocial adjustment...
  53. pmc Identification of polyclonal and monoclonal antibodies against tissue plasminogen activator in the antiphospholipid syndrome
    Cai Sheng Lu
    University of California, Los Angeles, CA 90095, USA
    Arthritis Rheum 52:4018-27. 2005
    ..To test the hypotheses that some plasmin-reactive anticardiolipin antibodies (aCL) may bind to tissue plasminogen activator (tPA) and that some of the tPA-reactive aCL may inhibit tPA activity...
  54. ncbi request reprint Mycophenolate mofetil or intravenous cyclophosphamide for lupus nephritis
    Ellen M Ginzler
    Division of Rheumatology, State University of New York Downstate Medical Center, Brooklyn, NY 11203, USA
    N Engl J Med 353:2219-28. 2005
    ..Since anecdotal series and small, prospective, controlled trials suggest that mycophenolate mofetil may be effective for treating lupus nephritis, larger trials are desirable...
  55. ncbi request reprint Two-year efficacy and safety of infliximab treatment in patients with active psoriatic arthritis: findings of the Infliximab Multinational Psoriatic Arthritis Controlled Trial (IMPACT)
    Christian E Antoni
    Clinical Immunology, Schering Plough Corporation, Kenilworth, New Jersey 07033 0530, USA
    J Rheumatol 35:869-76. 2008
    ..To investigate longterm efficacy/safety of infliximab over 2 years in patients with active psoriatic arthritis (PsA)...
  56. ncbi request reprint Treating axial manifestations in ankylosing spondylitis in the presence of peripheral arthritis
    Wonuk Lee
    Division of Rheumatology, Cedars Sinai Medical Center, Los Angeles, CA 90048, USA
    Nat Clin Pract Rheumatol 2:298-9. 2006